At 48 weeks, a regimen of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg was found to be similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL, and was associated with more favorable renal and bone safety markers.
http://www.drugs.com/clinical_trials/gilead-releases-tenofovir-alafenamide-data-hiv-trial-16058.html?
http://www.drugs.com/clinical_trials/gilead-releases-tenofovir-alafenamide-data-hiv-trial-16058.html?
No comments:
Post a Comment